The Supreme Court Nixes Claims to Isolated Genomic DNA
- Jorge A. Goldstein, Ph.D. and Robert W. Esmond, Ph.D.
The U.S. Supreme Court decided today that claims to isolated genomic DNA are not patentable subject matter and thus invalid. This decision rendered invalid patent claims owned by Myriad Genetics as well as thousands of patent claims of others to such molecules. However, Myriad’s claims to complementary DNA (cDNA) molecules were held to be valid.
Read the full summary of the decision in the attached PDF.